Lexapro vs Zoloft: What The Labels Actually Say

Escitalopram and sertraline are both selective serotonin reuptake inhibitors, and at the level of mechanism that is close to the whole story. Escitalopram is the S-enantiomer pulled out of citalopram, so it carries that older drug's chemistry and part of its history. Sertraline is structurally unrelated and arrived by a different route. The Lexapro prescribing information and the Zoloft prescribing information both describe blockade of the serotonin transporter as the presumed action, and neither claims something the other cannot do. Comparing them usefully means comparing their paperwork rather than their pharmacology.

That paperwork diverges more than you would expect. Escitalopram is cleared mainly through CYP3A4 and CYP2C19, and its two metabolites are roughly 7 and 27 times less potent at the transporter, so they add little. Sertraline produces N-desmethylsertraline, which is also far weaker. Both reach steady blood levels after about a week of daily dosing, and both carry the same boxed warning about increased suicidal thoughts and behaviors in younger age groups. Everything below is about the places where the two labels genuinely disagree with each other.

This is the difference that most often settles the question, and it is not close. The Zoloft label lists six approved conditions: major depressive disorder, obsessive compulsive disorder, panic disorder, post-traumatic stress disorder, social anxiety disorder and premenstrual dysphoric disorder. The Lexapro label lists two, major depressive disorder from age 12 up and generalized anxiety disorder from age 7 up. If your diagnosis is OCD or PTSD, only one of these two drugs has been approved by the FDA to treat it, and that is a hard fact rather than a preference.

The reverse holds too. Generalized anxiety disorder appears on the escitalopram label and does not appear on the sertraline label, so treating generalized anxiety with sertraline is off-label prescribing. Off-label is legal and routine, and a clinician may have sound reasons for it, but it means the agency has not reviewed adequate and well-controlled trials for that exact use. Ask which list your diagnosis falls on, and ask what the evidence looks like when it does not. That one question narrows the choice faster than any efficacy ranking will.

The 2018 Lancet network meta-analysis by Cipriani and colleagues remains the largest antidepressant comparison ever assembled: 522 double-blind randomized trials covering 116,477 participants, with unpublished regulatory data pulled in for escitalopram and sertraline among others. Outcomes were recorded as close to eight weeks as each trial allowed. Its two primary measures were response rate and acceptability, meaning discontinuation for any cause. PubMed record 29477251 carries the citation if you want to pull the original yourself rather than trust a summary.

On the head-to-head comparisons, escitalopram sat in the group rated more effective than the rest of the field, alongside agomelatine, amitriptyline, mirtazapine, paroxetine, venlafaxine and vortioxetine, with odds ratios spanning 1.19 to 1.96. Sertraline did not appear in that group. On acceptability, escitalopram and sertraline both sat in the more-tolerable group, odds ratios running 0.43 to 0.77.

So one edges the other on effect and they tie on staying power. That sounds decisive right up until you read the same paper's caveats.

Read the caveats and the ranking dissolves. Across all trials the differences in odds ratios between antidepressants ran from 1.15 to 1.55 for efficacy and 0.64 to 0.83 for acceptability, with wide credible intervals on most of the comparative analyses. The authors also reported that 46 of 522 trials were high risk of bias, 380 moderate and 96 low, with certainty of evidence moderate to very low. Escitalopram's comparisons happened to be among the better-graded ones, which counts for something, but nowhere near enough to declare a winner here.

So here is the honest framing. The gap between these two molecules is small next to the gap between one body and the next. Two readers with the same diagnosis on the same dose can have opposite experiences, and no trial average tells you which of you is which. The criteria that actually decide it are your diagnosis, your other prescriptions, whether you are pregnant or breastfeeding, and how you tolerate the first few weeks.

A licensed clinician weighs those against your history. A league table cannot.

On breastfeeding the evidence bases are not the same size, and the labels say so plainly. The Zoloft label cites a pooled analysis of 53 mother-infant pairs in which exclusively human-milk-fed infants averaged 2% of maternal sertraline serum levels, range 0 to 15%, with no adverse reactions observed. The Lexapro label cites a study of 8 nursing mothers on 10 to 20 mg daily whose exclusively breast-fed infants received about 3.9% of the maternal weight-adjusted dose, and separately notes reports of excessive sedation, restlessness, agitation, poor feeding and poor weight gain.

In pregnancy the two labels read much more alike. Both note that SSRI exposure in the month before delivery has been linked to a less than two-fold increase in the risk of postpartum hemorrhage, both describe poor neonatal adaptation, and both direct enrollment to the National Pregnancy Registry for Antidepressants. Persistent pulmonary hypertension of the newborn is not a point of difference between them. The Zoloft label carries it in Highlights, stating that third trimester use may increase the risk for persistent pulmonary hypertension and withdrawal in the neonate, and the Lexapro label carries it in Highlights too, stating that SSRI use particularly later in pregnancy may increase the risk for persistent pulmonary hypertension and symptoms of poor adaptation. The LactMed monograph for sertraline collects the underlying studies. Stopping an antidepressant in pregnancy carries its own relapse risk, which both labels state outright.

Escitalopram has a narrow dose window. The label sets 10 mg once daily as the starting dose and 20 mg as the maximum across every approved use and every age band, and holds the recommendation at 10 mg if you are elderly or have hepatic impairment. Sertraline runs much wider: 50 mg to start for depression and OCD, 25 mg for panic disorder, PTSD and social anxiety disorder, a therapeutic range of 50 to 200 mg, and increments no more often than weekly. More room to titrate is a genuine practical difference when a starting dose only half works.

The reason escitalopram stops at 20 mg is worth stating precisely, because it is widely misreported. The label says a fixed-dose trial demonstrated the effectiveness of both 10 mg and 20 mg but failed to demonstrate a greater benefit of 20 mg over 10 mg. It is a no-added-benefit ceiling. The label's own dose-response table shows what the extra 10 mg does reliably buy: insomnia rising from 7% at 10 mg to 14% at 20 mg, and diarrhea from 6% to 14%. More drug, more side effects, no demonstrated extra response.

Most comparison articles get this backwards, so read it slowly. The QT story belongs to citalopram. The Celexa label carries a dedicated warning on QT prolongation and Torsade de Pointes, tells prescribers to avoid it in congenital long QT syndrome, bradycardia, hypokalemia and several other settings, and to discontinue if QTc stays above 500 ms, plus a 40 mg daily maximum that drops to 20 mg over age 60, in hepatic impairment, or in CYP2C19 poor metabolizers.

That is the drug escitalopram was derived from.

Escitalopram did not inherit it. Its Warnings and Precautions section runs eleven subsections and none of them concerns QT. Sertraline's does: subsection 5.10 covers QTc prolongation, citing postmarketing reports of Torsade de Pointes and a thorough QTc study in 54 healthy adults, and advises caution if you carry QTc risk factors. The measured numbers land close together. Escitalopram's own thorough QT study in 113 healthy subjects found 10.7 msec of mean change at a supratherapeutic 30 mg, sertraline's found 10 msec at twice its maximum daily dose.

Both labels carry the same warning against the comparison you are about to make: adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug. Different enrolled groups, different durations, different reporting conventions. So treat what follows as two separate placebo-controlled pictures rather than a race. Sertraline's pooled table, 3,066 treated against 2,293 on placebo, shows nausea at 26% versus 12%, diarrhea or loose stools at 20% versus 10%, dry mouth 14% versus 9% and tremor 9% versus 2%. Escitalopram's depression table, 715 treated against 592 on placebo, shows nausea at 15% versus 7% and diarrhea at 8% versus 5%, while its generalized anxiety table puts nausea at 18% versus 8%. Sexual effects appear on both and are easy to lose in the noise: ejaculation disorder ran 9% against under 1% on placebo in the escitalopram depression trials and 14% against 2% in the anxiety trials, and ejaculation failure 8% against 1% for sertraline. If gut side effects are your main worry, raise it before you start.

CYP2D6 gets described as a sertraline problem, and the labels do not support that framing cleanly. Sertraline is labeled a CYP2D6 inhibitor with named substrates including propafenone, flecainide, atomoxetine, desipramine, dextromethorphan, metoprolol and venlafaxine, and its label concedes the effect is less prominent at lower doses while still warning about clinically important inhibition. Escitalopram is not exempt: 20 mg daily for 21 days raised desipramine peak concentration by 40% and total exposure by 100%, though its label calls the clinical significance of that unknown.

Half-life differences are smaller than the folklore suggests. Sertraline's average terminal elimination half-life is about 26 hours, and escitalopram's mean terminal half-life is about 27 to 32 hours. Both labels list nearly identical discontinuation symptoms, including dysphoric mood, irritability, dizziness and electric-shock sensations, and both recommend a gradual reduction in dose rather than abrupt cessation. Do not expect one to be meaningfully easier to stop on half-life grounds. Adding any other serotonergic drug to either raises serotonin syndrome risk, which both labels flag.

Price is the one place the answer is unambiguous, and it points at generics. In the CMS National Average Drug Acquisition Cost file published on 2 September 2026, generic escitalopram 10 mg tablets sit at $0.0394 each and generic sertraline 50 mg tablets at $0.03445 each, both flagged as generic for rate setting. Brand Lexapro 10 mg lists at $15.42 per tablet and brand Zoloft 50 mg at $14.92. Those are pharmacy acquisition costs rather than what you pay at the counter, but the ratio is the point.

Both are ordinary prescription drugs, so a telehealth visit is a reasonable route if your history is uncomplicated, and neither involves compounding. This page is information rather than medical advice. Three things worth asking: which of my diagnoses appears on this drug's approved list, what are you doing about my other prescriptions and CYP2D6, and what is the taper plan if this does not suit me. Look for a service that assigns a licensed clinician in your state, reviews your full medication list, and books follow-up rather than issuing one script.